Reports
Reports
Sale
The global thrombin market size was valued at USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe. The market is expected to grow at a CAGR of 5.50% during the forecast period of 2024-2032, with the values likely to rise from USD 701.3 million in 2024 to USD 1075.9 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Thrombin, also known as coagulation factor II, is a serine protease that regulates hemostasis and maintains blood coagulation. It is naturally produced in humans and is involved in the coagulation cascade. There are three thrombin products: bovine thrombin, human thrombin, and recombinant thrombin. All of them are approved by the Food and Drug Administration (FDA) for topical application as a solution, in combination with fibrinogen as a glue, or sprayed into a mist. As a hemostatic agent, thrombin can minimize blood loss during surgical procedures.
The thrombin market demand is driven by the rising incidence of hemophilia, an inherited bleeding disorder. It is estimated that 1 in every 6000-10,000 males have this bleeding disorder. Approximately 30,000 – 33,000 males are living with hemophilia in the United States, with the highest prevalence found in the Midwestern and Northeastern states. Another key driver is the extensive application of thrombin in the healthcare sector, owing to the growing prevalence of trauma cases. Moreover, the advancement in the healthcare infrastructure as well as the rising disposable income of the population is projected to contribute to the market growth in the forecast period.
Intensive Research to Expedite Thrombin Market Growth
Thrombin is extensively used in the hemostatic field. It can provide a direct clotting effect on the exposed blood, controlling minor oozing and bleeding during surgery. Intensive research activities by academic institutes and pharmaceutical companies revealed several therapeutic applications of thrombin including burn treatment, wound management, and tumor vasculature blockade therapy.
In November 2023, a study published in Nature, compared active (gelatin-thrombin-based product Floseal) and passive (modified absorbable polymers powder PerClot) hemostatic agents to find their effectiveness in controlling hepatic bleeding. It was observed that Floseal (active hemostatic group) was faster to achieve homeostasis than PerClot (passive hemostatic group) which was attributed to the presence of thrombin component in it. The continuous research and development efforts to find novel therapeutics and improve existing uses of thrombin are anticipated to contribute to the thrombin market share.
Growing Applications of Recombinant Thrombin
The regulatory health body FDA has approved many thrombin-based products including recombinant thrombin. Several drugs containing recombinant thrombin are currently undergoing clinical trials for their therapeutic homeostatic effect. In April 2023 , Baxter International Inc., announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. The new addition to its surgical portfolio was revealed at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product
Market Breakup by Dosage Form
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is experiencing significant growth in the demand for thrombin due to the increasing prevalence of blood disorders and trauma cases which requires the need for effective hemostatic agents. In addition, the robust support from government and non-government organizations is further accelerating market growth.
In August 2023 , Oklahoma Medical Research Foundation scientist Ray Rezaie received a USD 1.7 million grant from the National Institutes of Health (NIH) to support his work on blood clotting and the interaction of associated three molecules including thrombin. The funding will accelerate the research on mechanisms controlling clotting and inflammation, leading to promising medications for stroke, heart attack, and sepsis.
Europe also holds a considerable thrombin market share owing to the presence of well-established healthcare infrastructure. The existence of leading pharmaceutical companies is fuelling research and development (R&D) activities of thrombin, which is expanding the market size. In Asia Pacific, the growing population size, rising healthcare expenditure, and the increasing impetus for improved patient care are driving the market growth. The region is anticipated to offer lucrative growth opportunities for the key market players due to the surge in the adoption of thrombin-based hemostats in healthcare facilities.
In October 2023 , Aronora, a clinical-stage biotech based in the United States, secured investment from an early-stage life sciences investment fund NYBC Ventures. The funds will be used to develop the lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) and expand its manufacturing capacities. E-WE thrombin, an anticoagulant, has demonstrated positive results in phase 2a clinical trials. The increased investment in research and development by pharmaceutical companies and research organizations will improve the safety and efficacy of thrombin-based products, elevating thrombin market value in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product |
|
Breakup by Dosage Form |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Thrombin Market Overview
3.1 Global Thrombin Market Historical Value (2017-2023)
3.2 Global Thrombin Market Forecast Value (2024-2032)
4 Global Thrombin Market Landscape*
4.1 Global Thrombin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Thrombin Product Landscape
4.2.1 Analysis by Product
4.1.2 Analysis by Dosage Form
5 Global Thrombin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Thrombin Market Segmentation (2017-2032)
6.1 Global Thrombin Market (2017-2032) by Product
6.1.1 Market Overview
6.1.2 Bovine Thrombin
6.1.3 Human Thrombin
6.1.4 Recombinant Thrombin
6.2 Global Thrombin Market (2017-2032) by Dosage Form
6.2.1 Market Overview
6.2.2 Powder Form
6.2.3 Solution Form
6.3 Global Thrombin Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centre and Clinics
6.3.4 Academics and Research Institutes
6.3.5 Others
6.4 Global Thrombin Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Thrombin Market (2017-2032)
7.1 North America Thrombin Market (2017-2032) by Product
7.1.1 Market Overview
7.1.2 Bovine Thrombin
7.1.3 Human Thrombin
7.1.4 Recombinant Thrombin
7.2 North America Thrombin Market (2017-2032) by Dosage Form
7.2.1 Market Overview
7.2.2 Powder Form
7.2.3 Solution Form
7.3 North America Interventional Radiology Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Thrombin Market (2017-2032)
8.1 Europe Thrombin Market (2017-2032) by Product
8.1.1 Market Overview
8.1.2 Bovine Thrombin
8.1.3 Human Thrombin
8.1.4 Recombinant Thrombin
8.2 Europe Thrombin Market (2017-2032) by Dosage Form
8.2.1 Market Overview
8.2.2 Powder Form
8.2.3 Solution Form
8.3 Europe Thrombin Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Thrombin Market (2017-2032)
9.1 Asia Pacific Thrombin Market (2017-2032) by Product
9.1.1 Market Overview
9.1.2 Bovine Thrombin
9.1.3 Human Thrombin
9.1.4 Recombinant Thrombin
9.2 Asia Pacific Thrombin Market (2017-2032) by Dosage Form
9.2.1 Market Overview
9.2.2 Powder Form
9.2.3 Solution Form
9.3 Asia Pacific Cryostat Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Thrombin Market (2017-2032)
10.1 Latin America Thrombin Market (2017-2032) by Product
10.1.1 Market Overview
10.1.2 Bovine Thrombin
10.1.3 Human Thrombin
10.1.4 Recombinant Thrombin
10.2 Latin America Thrombin Market (2017-2032) by Dosage Form
10.2.1 Market Overview
10.2.2 Powder Form
10.2.3 Solution Form
10.3 Latin America Thrombin Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Thrombin Market (2017-2032)
11.1 Middle East and Africa Thrombin Market (2017-2032) by Product
11.1.1 Market Overview
11.1.2 Bovine Thrombin
11.1.3 Human Thrombin
11.1.4 Recombinant Thrombin
11.2 Middle East and Africa Thrombin Market (2017-2032) by Dosage Form
11.2.1 Market Overview
11.2.2 Powder Form
11.2.3 Solution Form
11.3 Middle East and Africa Interventional Radiology Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Johnson and Johnson
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Baxter International, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Shanghai RAAS Blood Products Co., Ltd.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Japan Blood Products Organization
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mochida Pharmaceutical Co., Ltd
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Haematologic Technologies Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 GE Healthcare
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Hualan Biological
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 AMRESCO Inc
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 CSL Behring
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Mallinckrodt Pharmaceuticals
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 BIOFAC A/S
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Biomed-Lublin S.A.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Hualan Biological Engineering, Inc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Thrombin Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe.
The market is anticipated to grow at a CAGR of 5.50% during the forecast period of 2024-2032, likely to reach a market value of USD 1075.9 million by 2032.
The increased expenditure on healthcare and the rising patient awareness are some of the factors contributing to the increasing market demand.
The growing application of thrombin-based products, including recombinant thrombin in the healthcare sector, is the major trend in the market. In April 2023, Baxter International Inc. announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
The various products in the market are bovine, human, and recombinant thrombin.
Based on the dosage form, the market is segmented into powder form and solution form.
Major end users of thrombin include hospitals, diagnostic centers and clinics, academics, and research institutes, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Pfizer Inc., Johnson and Johnson, Baxter International, Inc., Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd, Haematologic Technologies Inc., GE Healthcare, Hualan Biological, AMRESCO Inc, CSL Behring, Mallinckrodt Pharmaceuticals, BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.